Oxford BioDynamics Plc (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product, EpiSwitch CiRT, predicts how a patient will respond to immune checkpoint inhibitor therapies. OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring.
Axol Bioscience supplies cells and custom laboratory services to model human disease. We spearhead the use of advanced in vitro methods and human pluripotent stem cell (hiPSC) technology for the generation of robust and physiologically relevant platforms for drug discovery. Axol offers custom made-to-order differentiated human iPSC-derived neuron products from a suite of ALS disease-affected cell lines. We currently have six cell lines available representing three genotypic profiles associated with motor neuron disease.
Genomenon empowers pharma and biotech companies with the genomic intelligence required to develop and go-to-market with targeted therapies for rare genetic diseases and cancers. Our unique blend of AI technology and human expertise enables us to quickly and efficiently identify relevant pathogenic variants and biomarkers, analyze target patient populations, validate disease prevalence estimates, and increase diagnostic yield. Leveraging Mastermind, our knowledgebase of empirical genomic evidence, Genomenon’s expert team of genomic scientists delivers precisely tailored data solutions and insights to minimize risk and keep drug programs on track."
PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments and reduce the attrition rate in clinical development. Our capabilities include behavioral testing, surgical models, electrophysiology, translational EEG, quantitative histology, biomarker analysis, bioanalysis and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.
NeuroProof Systems GmbH is a CRO for the preclinical screening and testing of new drugs in its developed disease models. With its functional phenotypic screening of human iPSC-derived neuronal cell cultures, the company delivers a compound profiling of potential new therapies.
NetraMark uses novel AI to unearth statistically significant patient subpopulations, along with the defining variables, to improve clinical development of innovative medicines. NetraAI is a unique machine learning system that provides an intuitive interface for scientists to interact with multimodal datasets to uncover patient connections related to efficacy, toxicity and placebo response. The Company’s explainable AI allows clinical development teams to optimize learnings from small datasets to enrich patient populations to speed development.
PRC Clinical is the CRO of choice for ALS trials, providing specialty CRO services for over 20 years. Our innovative approach to executing studies combines cutting-edge technology with extensive experience and deep therapeutic knowledge. PRC Clinical delivers strategic solutions and high-touch approaches that ensure patients get the support they need to remain engaged and enrolled throughout your trial. Along with our host of online management tools, we ensure your trial receives the TLC it deserves from PRC.
ARG is a contract research organization focused on oncology, immunology, and neurology, providing comprehensive clinical program development services ranging from planning to commercialization, achieving over 50 market authorizations to date. Founded in 2004 with the vision that every project should be highly individualized, ARG has experienced consistent growth across the globe, expanding our range to include drug and device strategic consulting, clinical trial management services, as well as clinical data and analytic solutions. ARG uses first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.
With more than 35 products launched in over 60 countries, the Zydis® ODT (orally disintegrating tablet) fast-dissolve technology continues to be the world’s best-in-class ODT technology. The Zydis fast-dissolve platform consists of three technologies: Zydis ODT, Zydis Ultra, and Zydis Bio. Zydis ODT is a unique freeze-dried dosage form that disperses within three seconds without the need for water. Zydis Ultra technology offers enhanced taste-masking capabilities, increased drug loading, and the potential for functional coating. Zydis Bio technology offers a formulation strategy for oral delivery of peptides, allergens, and viral vaccines.
Inoviv is a biotechnology company using cutting-edge LC-MS based proteomics to accelerate the biopharma R&D pipeline. With deep expertise in neurodegenerative diseases, Inoviv has developed fully quantitative biomarker panels (ALS, AD, PD) to support pre-clinical and clinical studies across the US, the EU and Asia. This increases clinical trial success rates by demonstrating treatment efficacy, elucidating drug MoA and stratifying patient populations. Inoviv is advised by world-class clinical academics (the University of Oxford, Charité University Hospital) and operates from CLIA-accredited labs in the US and GLP labs in the UK.